Systematic Review and Meta-Analysis of the Effect of Anticoagulation on Outcomes After Endovascular Aneurysm Repair

Abstract

Purpose:

Our objective was to investigate whether patients who receive anticoagulation therapy have different outcomes after endovascular aneurysm repair (EVAR) from those who do not.

Materials and Methods:

We conducted a systematic review of studies that compared outcomes of EVAR in patients who were on therapeutic anticoagulation vs those who were not. We developed and reported the review in accordance with the PRISMA guidelines with a registered protocol (CRD42022375894). The Ovid interface was used to search Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica Database (EMBASE), and Cochrane Central Register of Controlled Trials (CENTRAL) up to November 2022. The quality of studies was assessed with the Newcastle-Ottawa Scale (NOS) (maximum score=9), and the evidence was appraised with the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. The hazard ratio (HR) and 95% confidence interval (CI) was the effect estimate in time-to-event meta-analyses, calculated using the inverse-variance statistical method and random-effects models.

Results:

Sixteen studies qualified for inclusion reporting a total of 35 739 individuals. Anticoagulated patients had a statistically significantly higher hazard of death (HR=1.93, 95% CI=1.03-3.63), endoleak (HR=2.13, 95% CI=1.55-2.93), reintervention (HR=1.79, 95% CI=1.27-2.52), and aneurysm sac expansion (HR=2.72, 95% CI=1.57-4.72) than patients not receiving anticoagulation therapy. The median score on the NOS was 7 (range=4-9). The certainty of evidence was very low for mortality and reintervention and low for endoleak and sac expansion.

Conclusions:

Anticoagulation is a poor prognostic factor after standard EVAR and should be considered in decision-making, consent processes, and surveillance strategies.

Clinical Impact

The number of individuals who take anticoagulation treatment has been rapidly increasing over the recent years. We aimed to investigate the effect of such treatment on outcomes after endovascular aneurysm repair (EVAR). Anticoagulated patients were found to have increased mortality, endoleak, and reintervention rates after EVAR compared to their non-anticoagulated counterparts. Anticoagulation therapy has a prognostic role in EVAR and should be considered in decision making and EVAR surveillance. Anticoagulated patients need to be informed of the higher failure rates of EVAR, and intensified surveillance strategies may need to be implemented in this patient cohort.

Keywords

aortic aneurysm endovascular aneurysm repair EVAR anticoagulation warfarin

Get full access to this article

View all access options for this article.

References

Wanhainen

Verzini

Van Herzeele

, et al. Editor’s choice—European Society for Vascular Surgery (ESVS) 2019 clinical practice guidelines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endovasc Surg. 2019;57(1):8–93.

Antoniou

Torella

Editor’schoice—endovascularvs. Open repair for abdominal aortic aneurysm: systematic review and meta-analysis of updated peri-operative and long term data of randomised controlled trials. Eur J Vasc Endovasc Surg. 2020;59(3):385–397.

Chen

Yeh

Ulloa

, et al. Frailty among veterans undergoing abdominal aortic aneurysm repair. Ann Vasc Surg. 2023;92:18–23.

Hutchens

Hung

Briffa

, et al. Antithrombotic therapy in atrial fibrillation management in Western Australia: temporal trends and evidence-treatment gaps. Heart Lung Circ. 2021;30(7):955–962.

Kotalczyk

Gue

Potpara

, et al. Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom are changes on the horizon. Expert Opin Pharmacother. 2021;22(8):1061–1070.

Higgins

JPT

Thomas

Chandler

, et al. Cochrane Handbook for Systematic Reviews of Interventions (Version 6.0). London, England: Cochrane; 2019.

Antoniou

Mani

Enhancing the reporting of systematic reviews and meta-analyses in vascular surgery: PRISMA 2020. Eur J Vasc Endovasc Surg. 2021;62(4):664–666.

The Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Date unknown. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed April 1, 2023.

Antoniou

GA.

The GRADE approach to appraising the evidence or how to increase the credibility of your research. Am J Surg. 2020;220(2):290–293.

10.

Tierney

Stewart

Ghersi

, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.

11.

Antoniou

Smith

CT.

A guide on meta-analysis of time-to-event outcomes using aggregate data in vascular and endovascular surgery. J Vasc Surg. 2020;71(3):1002–1005.

12.

DerSimonian

Laird

Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.

13.

Sterne

JAC

Sutton

Ioannidis

JPA

, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.

14.

Fairman

Carpenter

Baum

, et al. Potential impact of therapeutic warfarin treatment on type II endoleaks and sac shrinkage rates on midterm follow-up examination. J Vasc Surg. 2002;35(4):679–685.

15.

Biebl

Hakaim

Oldenburg

, et al. Does chronic oral anticoagulation with warfarin affect durability of endovascular aortic aneurysm exclusion in a midterm follow-up? J Endovasc Ther. 2005;12(1):58–65.

16.

Bobadilla

Hoch

Leverson

, et al. The effect of warfarin therapy on endoleak development after endovascular aneurysm repair (EVAR) of the abdominal aorta. J Vasc Surg. 2010;52(2):267–271.

17.

Abularrage

Crawford

Conrad

, et al. Preoperative variables predict persistent type 2 endoleak after endovascular aneurysm repair. J Vasc Surg. 2010;52(1):19–24.

18.

Johnson

Chiang

Eldrup-Jorgensen

, et al. Effect of chronic oral anticoagulation with warfarin on the durability and outcomes of endovascular aortic aneurysm repair. J Vasc Surg. 2013;58(2):319–323.

19.

De Rango

Verzini

Parlani

, et al. Safety of chronic anticoagulation therapy after endovascular abdominal aneurysm repair (EVAR). Eur J Vasc Endovasc Surg. 2014;47(3):296–303.

20.

Wild

Dattani

Stather

, et al. Effect of anticoagulation and antiplatelet therapy on incidence of endoleaks and sac size expansions after endovascular aneurysm repair. Ann Vasc Surg. 2014;28(3):554–559.

21.

Kumar

Cowled

Boult

, et al. Type II endoleak after endovascular aneurysm repair: natural history and treatment outcomes. Ann Vasc Surg. 2017;44:94–102.

22.

Álvarez Marcos

Llaneza Coto

Franco Meijide

, et al. Effect of antiplatelet therapy on aneurysmal sac expansion associated with type II endoleaks after endovascular aneurysm repair. J Vasc Surg. 2017;66(2):396–403.

23.

Seike

Tanaka

Fukuda

, et al. Influence of warfarin therapy on the occurrence of postoperative endoleaks and aneurysm sac enlargement after endovascular abdominal aortic aneurysm repair. Interact Cardiovasc Thorac Surg. 2017;24:615–618.

24.

Castelli

Deluca

Guillermo

, et al. Oral anticoagulation in aortic endovascular reinterventions. Rev Argent Cardiol. 2019;87:15–18.

25.

Flohr

Snow

Aziz

The fate of endoleaks after endovascular aneurysm repair and the impact of oral anticoagulation on their persistence. J Vasc Surg. 2021;74(4):1183–1192.e5.

26.

D’Oria

Di Girolamo

Calvagna

, et al. Remodeling of abdominal aortic aneurysm sac following endovascular aortic repair: association with clinical, surgical, and genetic factors. Cardiovasc Pathol. 2022;58:107405.

27.

Kong

Balceniuk

Mix

, et al. Long-term anticoagulation is associated with type II endoleaks and failure of sac regression after endovascular aneurysm repair. J Vasc Surg. 2022;76(2):437–444.e2.

28.

Morisaki

Matsubara

Furuyama

, et al. Effects of antithrombotic therapy on abdominal aortic aneurysm sac size after endovascular repair in patients with favorable neck anatomy. J Vasc Interv Radiol. 2022;33(2):113–119.

29.

Lal

Zhou

, et al; OVER Veterans Affairs Cooperative Study Group. Predictors and outcomes of endoleaks in the veterans affairs open versus endovascular repair (OVER) trial of abdominal aortic aneurysms. J Vasc Surg. 2015;62:1394–1404.

30.

Buck

Herrmann

, et al; Vascular Study Group of New England.Risk factors and consequences of persistent type II endoleaks. J Vasc Surg. 2016;63:895–901.

31.

Jones

Atkins

Brewster

, et al. Persistent type 2 endoleak after endovascular repair of abdominal aortic aneurysm is associated with adverse late outcomes. J Vasc Surg. 2007;46(1):1–8.

32.

Pineda

Calligaro

Tyagi

, et al. Late type II endoleaks after endovascular aneurysm repair require intervention more frequently than early type II endoleaks. J Vasc Surg. 2018;67(2):449–452.

33.

Ultee

KHJ

Büttner

Huurman

, et al. Editor’s choice—systematic review and meta-analysis of the outcome of treatment for type II endoleak following endovascular aneurysm repair. Eur J Vasc Endovasc Surg. 2018;56(6):794–807.

34.

Sidloff

Stather

Choke

, et al. Type II endoleak after endovascular aneurysm repair. Br J Surg. 2013;100:1262–1270.

35.

Lazarides

Georgiadis

Charalampidis

, et al. Impact of long-term warfarin treatment on EVAR durability: a meta-analysis. J Endovasc Ther. 2014;21(1):148–153.

36.

Antoniou

GA.

Risk stratification and risk specific surveillance for endovascular aneurysm repair. Eur J Vasc Endovasc Surg. 2020;60:950–951.

37.

Ul-Mulk

Antoniou

GA.

Prognostic prediction models for endovascular abdominal aortic aneurysm repair: protocol for a scoping review. BMJ Open. 2022;12:e061420.

38.

Antoniou

Schermerhorn

Forbes

, et al. Risk factors, risk stratification and risk-specific surveillance strategies after endovascular aneurysm repair: study protocol for a Delphi study by the International RIsk Stratification in EVAR (IRIS-EVAR) working group. BMJ Open. 2022;12:e055803.

39.

Lalys

Durrmann

Duménil

, et al. Systematic review and meta-analysis of preoperative risk factors of type II endoleaks after endovascular aneurysm repair. Ann Vasc Surg. 2017;41:284–293.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.10 MB

0.01 MB

0.02 MB

0.01 MB